天然药物衍生碳点作为一种新的口服抗氧化剂给药策略,用于性结肠炎治疗
Tong Wu1, Xue Bai2, Yue Zhang3
1School of Chinese Materia Medica, Beijing University of Chinese Medicine, Beijing, 100029, China.
Journal of nanobiotechnology
|August 26, 2024
概括
来自磁铁和药用叶片 (MML-CDs) 的新型碳点显示出治疗性结肠炎 (UC) 的前景. 口服MML-CD可缓解炎症并修复肠道屏障损伤,为这种慢性疾病提供了一种新的治疗策略.
科学领域:
- 生物材料科学 生物材料科学
- 纳米技术纳米技术
- 胃肠病学 胃肠病学
背景情况:
- 性结肠炎 (UC) 是一种慢性肠道炎症,缺乏特定的治疗方法.
- 自然药物具有潜力,但面临生物可用性挑战.
- 开发有效的UC疗法仍然是全球医疗保健的优先事项.
研究的目的:
- 为了合成和描述新的功能性碳点 (MML-CDs) 用于UC治疗.
- 评估口服的MML-CDs在缓解UC方面的治疗疗效.
- 阐明MML-CDs在治疗肠道炎症中的潜在机制.
主要方法:
- 磁铁和药用叶子衍生的碳点 (MML-CDs) 的水热合成.
- 关于MML-CD的尺寸,结构和特性 (稳定性,ROS清除,生物相容性) 的表征.
- 在UC模型中对MML-CDs口服的体内评估.
主要成果:
- 合成的MML-CD显示出超小的纳米尺寸和Fe-doped表面结构.
- MML-CDs表现出优异的胃肠道稳定性,ROS消除和生物相容性.
- 口服的MML-CDs通过改善血液静止,抑制炎症和氧化应激,上调紧结蛋白质和调节肠道微生物群,显著减轻UC.
结论:
- 绿色合成的MML-CD有效缓解UC的肠道出血和结肠炎症.
- MML-CDs修复结肠屏障损伤并调节肠道炎症微环境.
- MML-CDs代表了性结肠炎的新和有效的口服治疗策略.
相关概念视频
Drugs for Treatment of Ulcerative Colitis in IBD
130
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
130
Peptic Ulcer Disease IV: Management
78
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
78
Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents
415
In the intricate landscape of the gastric lumen, excessive acid secretion disrupts the natural defense mechanisms, weakening the mucus-bicarbonate barrier. This vulnerability allows pepsin to infiltrate epithelial cells, digesting mucosal proteins and triggering erosion, leading to ulcer formation.
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
415
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
377
The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
377
Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors
358
Peptic ulcer disease, commonly called PUD, represents a multifaceted condition characterized by disruptions in the lining of the gastrointestinal (GI) tract. Central to the protection of the gastrointestinal lining is the mucosal-bicarbonate barrier. This physiological defense mechanism is a formidable shield against the corrosive effects of gastric acid and pepsin secretion in the stomach. Its role is pivotal in maintaining the structural integrity of the stomach's inner lining.
358
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
329
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
329


